Loading stock data…
ETON
$29.84+0.19 (+0.64%)
After Hours$29.84+0.00 (+0.00%)· Last close May 11
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eton Pharmaceuticals, Inc. in the Healthcare sector is trading at $29.57. The stock is currently near its 52-week high of $32.31, remaining 58.2% above its 200-day moving average. Technical signals show overbought RSI of 75 and bullish MACD crossover, explaining why ETON maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 75) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.84
Potential Upside
5%
Whystock Fair Value$31.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$626.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.59%
Volume
Today's trading volume
222,348
Recent News
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +139.30% and +33.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -54.72% and -9.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals (ETON) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How The Hemangeol Deal Is Rewriting The Story For Eton Pharmaceuticals (ETON)
The fair value estimate for Eton Pharmaceuticals sits at $39.33, with the latest update keeping that headline price target unchanged. That stability comes as analysts rework their models around the Hemangeol acquisition, weighing its role in future revenue, earnings mix, and how much confidence to place in the planned May commercialization. As you read on, you will see what is driving the evolving analyst story and how to keep track of the key signals. Stay updated as the Fair Value for Eton...
Eton Pharmaceuticals (ETON) Appoints Judith M. Matthews as New CFO
Eton Pharmaceuticals Inc. (NASDAQ:ETON) is one of the best NASDAQ growth stocks to buy and hold forever. On April 16, Eton Pharmaceuticals announced a succession plan for its Chief Financial Officer, appointing Judith M. Matthews as Executive Vice President of Accounting and Finance. Matthews is scheduled to officially assume the CFO role on June 1, […]